Darragh F Halpenny1, Andrew Plodkowski2, Gregory Riely3, Junting Zheng4, Anya Litvak3, Chaya Moscowitz4, Michelle S Ginsberg2. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: halpennd@mskcc.org. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 3. Department of Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Abstract
INTRODUCTION: We studied computed tomography (CT) features associated with BRAF mutated lung cancer. MATERIALS AND METHODS: CT features of BRAF mutated lung cancers were compared to stage matched lesions without BRAF mutation. RESULTS: 47 (25%) patients with BRAF mutation and 141 (75%) without BRAF mutation were included. BRAF lesions were most frequently solid 37 (84%), spiculated 22 (50%), and peripheral 37 (84%). No feature of the primary tumor was significantly different between BRAF and non-BRAF groups. BRAF patients were more likely than KRAS patients to have pleural metastases [5 (11%) vs 0 (0%), p=0.045]. CONCLUSION: No feature of the primary tumor differentiates BRAF lesions from non-BRAF lesions.
INTRODUCTION: We studied computed tomography (CT) features associated with BRAF mutated lung cancer. MATERIALS AND METHODS: CT features of BRAF mutated lung cancers were compared to stage matched lesions without BRAF mutation. RESULTS: 47 (25%) patients with BRAF mutation and 141 (75%) without BRAF mutation were included. BRAF lesions were most frequently solid 37 (84%), spiculated 22 (50%), and peripheral 37 (84%). No feature of the primary tumor was significantly different between BRAF and non-BRAF groups. BRAFpatients were more likely than KRASpatients to have pleural metastases [5 (11%) vs 0 (0%), p=0.045]. CONCLUSION: No feature of the primary tumor differentiates BRAF lesions from non-BRAF lesions.
Authors: Maximilian Diehn; Christine Nardini; David S Wang; Susan McGovern; Mahesh Jayaraman; Yu Liang; Kenneth Aldape; Soonmee Cha; Michael D Kuo Journal: Proc Natl Acad Sci U S A Date: 2008-03-24 Impact factor: 11.205
Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2002-06-09 Impact factor: 49.962
Authors: Pascal O Zinn; Bhanu Mahajan; Bhanu Majadan; Pratheesh Sathyan; Sanjay K Singh; Sadhan Majumder; Ferenc A Jolesz; Rivka R Colen Journal: PLoS One Date: 2011-10-05 Impact factor: 3.240